The European Commission has approved United States-based Bristol Myers Squibb's (NYSE: BMY) and United States-based Acceleron Pharma Inc's (NASDAQ: XLRN) Reblozyl (luspatercept), it was reported on Friday.
The product is intended for the treatment of adult patients with transfusion-dependent anaemia because of very low-, low- and intermediate-risk myelodysplastic syndromes with ring sideroblasts, who had an unsatisfactory response or are ineligible for erythropoietin-based therapy and for adult patients with transfusion-dependent anaemia associated with beta thalassemia.
The product is the first and only erythroid maturation agent approved in the European Union. It has received approval based on the data from the pivotal Phase three MEDALIST and BELIEVE studies, assessing the ability of the product to effectively address anaemia associated with myelodysplastic syndromes and beta thalassemia, respectively.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients